Polatuzumab vedotin
From IDWiki
- Anti-CD79b antibody with a humanized IgG1 monoclonal antibody and monomethyl auristatin E (MMAE, an antimitotic agent)
- Indicated for diffuse large B-cell lymphoma
- Adverse effects
- Include rash, anorexia, diarrhea, nausea/vomiting, fatigue, myelosuppression and opportunistic infections
- Infusion reactions can occur as late as 24 hours post-infusion
- Tumour lysis syndrome
- Hepatotoxicity, mostly low-grade and reversible
- Serious infections, including Pneumocystis jirovecii, bacteremia, herpes zoster virus, CMV, and case reports of PML
- Peripheral neuropathy
